Benzinga | Sep 17, 2020 05:37AM EDT

Ascendiant Capital Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $7

Ascendiant Capital initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $7.